About Immunoglobulin-binding protein 1
Immunoglobulin-binding protein 1 (IGBP1) is a protein
from Homo sapiens identified by UniProt accession
P78318, 339 residues long.
MolForge cross-references it against 0 known binders and
384 disease associations.
Target properties
| Protein name | Immunoglobulin-binding protein 1 |
| UniProt accession | P78318 |
| Gene | IGBP1 |
| Organism | Homo sapiens |
| Length | 339 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (384)
Diseases linked to this target (Open Targets).
- corpus callosum agenesis-intellectual disability-coloboma-micrognathia syndrome · score 0.54
- Agenesis of the corpus callosum - intellectual disability - coloboma - micrognathia · score 0.43
- neurodegenerative disease · score 0.26
- breast cancer · score 0.07
- hepatocellular carcinoma · score 0.05
- esophageal squamous cell carcinoma · score 0.05
- Systemic lupus erythematosus · score 0.05
- neoplasm · score 0.04
- cancer · score 0.03
- allergic asthma · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P78318-F1 | alphafold | PREDICTED | 81.73 | — |
Amino-acid sequence (339 residues)
MAAEDELQLP RLPELFETGR QLLDEVEVAT EPAGSRIVQE KVFKGLDLLE KAAEMLSQLD LFSRNEDLEE IASTDLKYLL VPAFQGALTM KQVNPSKRLD HLQRAREHFI NYLTQCHCYH VAEFELPKTM NNSAENHTAN SSMAYPSLVA MASQRQAKIQ RYKQKKELEH RLSAMKSAVE SGQADDERVR EYYLLHLQRW IDISLEEIES IDQEIKILRE RDSSREASTS NSSRQERPPV KPFILTRNMA QAKVFGAGYP SLPTMTVSDW YEQHRKYGAL PDQGIAKAAP EEFRKAAQQQ EEQEEKEEED DEQTLHRARE WDDWKDTHPR GYGNRQNMG
Explore Immunoglobulin-binding protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets